Clinical Trials Sponsored by GeneScience Pharmaceuticals Co., Ltd.

Total 3755 results

Betta Pharmaceuticals Co., Ltd.

Suspended

Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib and Arsenic Trioxide in Treating Non-small-cell Lung Cancer Patients With Resistance to EGFR-TKI

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Sequential and Maintenance Icotinib Plus Chemotherapy Versus Icotinib Maintenance After Chemotherapy in Advanced NSCLC

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Completed

Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients (ICOGEN)

Non-small Cell Lung Cancer

China
Jacobio Pharmaceuticals Co., Ltd.

Not yet recruiting

JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Solid Tumors
Lynk Pharmaceuticals Co., Ltd

Recruiting

A Study of LNK01001 Capsule in Subjects With Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
Ascletis Pharmaceuticals Co., Ltd.

Not yet recruiting

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Acne
NucMito Pharmaceuticals Co. Ltd.

Recruiting

A Phase 1 Study of NM6603 in Advanced Solid Tumors

Cancers

United States
Betta Pharmaceuticals Co., Ltd.

Recruiting

BPB-101 in Subjects With Metastatic or Locally Advanced Solid Tumors

Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Study of BPI-460372 in Advanced Solid Tumor Patients

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of BPI-21668

Advanced Solid Tumor

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1/2 Study of BPI-361175 in Subjects With Advanced Solid Tumors

Non-small Cell Lung Cancer

China
Betta Pharmaceuticals Co., Ltd.

Recruiting

A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors

Metastatic Cancer | Malignant Neoplasms

China
Ascletis Pharmaceuticals Co., Ltd.

Recruiting

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Recurrent Glioblastoma

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation

NSCLC | Advanced Solid Tumor | CRC

United States
Betta Pharmaceuticals Co., Ltd.

Recruiting

Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors

Head and Neck Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Solid Tumor

China
TaiwanJ Pharmaceuticals Co., Ltd

Not yet recruiting

Effect of JKB-122 on Prednisolone and Azathioprine Induced Remission in Autoimmune Hepatitis (AIH)

Autoimmune Hepatitis
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A Study of JAB-3312 in Adult Patients With Advanced Solid Tumors in China

Breast Cancer | Colorectal Cancer | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Other Solid Tumors | Pancreatic Ductal Carcinoma

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First-in-Human Study of JAB-3068 (SHP2 Inhibitor) in Adult Patients With Advanced Solid Tumors in China

Head and Neck Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Other Metastatic Solid Tumors

China
Jacobio Pharmaceuticals Co., Ltd.

Recruiting

A First in Human, Dose Escalation Study of JAB-3068 （SHP2 Inhibitor） in Adult Patients With Advanced Solid Tumors

Head and Neck Cancer | Esophageal Cancer | Non-small Cell Lung Cancer | Other Metastatic Solid Tumors

United States
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Hepatitis B, Chronic

China
Argorna Pharmaceuticals Co., LTD

Completed

Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster

SARS-CoV-2

China
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-171-101 Study in Patients With MPS I

Mucopolysaccharidosis I

United States, Brazil, Japan
JCR Pharmaceuticals Co., Ltd.

Active, not recruiting

An Extension Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Mucopolysaccharidosis II

Japan
Argorna Pharmaceuticals Co., LTD

Completed

A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults

SARS-CoV-2

China
Foresee Pharmaceuticals Co., Ltd.

Terminated

A Phase 2/3 Study to Evaluate FP-025 in Patients With Severe to Critical COVID 19

Severe to Critical COVID 19 With Associated ARDS

United States
Jacobio Pharmaceuticals Co., Ltd.

Completed

A Food Effect Study of JAB-21822 in Healthy Subjects

Food Effect in Healthy Participants

China
Lynk Pharmaceuticals Co., Ltd

Completed

A Study of LNK01001 Capsule in Patients With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

China
Lynk Pharmaceuticals Co., Ltd

Completed

A Study of LNK01001 Capsule in Patients With Ankylosing Spondylitis

Ankylosing Spondylitis

China
Lynk Pharmaceuticals Co., Ltd

Completed

A Study of LNK01001 Capsule in Moderately to Severely Active Rheumatoid Arthritis

Rheumatoid Arthritis

China
Lynk Pharmaceuticals Co., Ltd

Withdrawn

A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Primary Myelofibrosis | Polycythemia Vera | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States
Betta Pharmaceuticals Co., Ltd.

Completed

A Food-Effect Study of BPI-16350 in Healthy Subjects

Healthy

China
Ascletis Pharmaceuticals Co., Ltd.

Active, not recruiting

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

SARS CoV 2 Infection

China
JCR Pharmaceuticals Co., Ltd.

Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis Type II

Mucopolysaccharidosis II

Japan
JCR Pharmaceuticals Co., Ltd.

Completed

A Study of JR-141 in Patients With Mucopolysaccharidosis II

Mucopolysaccharidosis II

Brazil
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Healthy

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Healthy

China
Betta Pharmaceuticals Co., Ltd.

Active, not recruiting

Icotinib as Adjuvant Therapy Compared With Standard Chemotherapy in Stage II-IIIA NSCLC With EGFR-mutation (EVIDENCE)

Non-small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

Healthy

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Chronic Hepatitis C
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

HCV

China
TaiwanJ Pharmaceuticals Co., Ltd

Unknown

A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule

Autoimmune Hepatitis
Betta Pharmaceuticals Co., Ltd.

Unknown

High Dose Icotinib With Sequential SRS For NSCLC Patients Harboring EGFR Mutation With Brain Metastases

Non-small Cell Lung Cancer | Brain Metastases

China
Betta Pharmaceuticals Co., Ltd.

Unknown

The Absorption, Metabolism and Excretion of [14C]Ensartinib in Human

ALK-POSITIVE NSCLC

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Efficacy and Safety of Danoprevir/r + PR 12-week Triple Therapy in Treatment-Naive, Non-Cirrhotic, G1 CHC China II

Chronic Hepatitis C
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as Consolidation Therapy After Chemoradiotherapy in EGFR-Mutant Stage IIIA-IIIB Non-small Cell Lung Cancer

Non Small Cell Lung Cancer Stage IIIB | EGFR Gene Mutation | Non Small Cell Lung Cancer Stage IIIA

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

A Study to Evaluate the Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

Chronic Hepatitis c

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Pharmacokinetics and Safety of ASC16 Tablets in Healthy Volunteers in China

HCV

China
Betta Pharmaceuticals Co., Ltd.

Unknown

Icotinib as First-line and Maintenance Treatment in EGFR Mutated Patients With Lung Adenocarcinoma

Adenocarcinoma | EGFR Positive Non-small Cell Lung Cancer

China
Ascletis Pharmaceuticals Co., Ltd.

Completed

Safety, Tolerability and Pharmacokinetics of Danoprevir/r in Healthy Volunteers China

Healthy

Clinical Trials Sponsored by GeneScience Pharmaceuticals Co., Ltd.

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Netherlands

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations